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Objectives
The aim of the study was to describe agreement between the QRISK2, Framingham and Data
Collection on Adverse Events of Anti-HIV Drugs (D:A:D) cardiovascular disease (CVD) risk
calculators in a large UK study of people living with HIV (PLWH).
Methods
PLWH enrolled in the Pharmacokinetic and Clinical Observations in People over Fifty (POPPY)
study without a prior CVD event were included in this study. QRISK2, Framingham CVD and the
full and reduced D:A:D CVD scores were calculated; participants were stratified into ‘low’ (< 10%),
‘intermediate’ (10–20%) and ‘high’ (> 20%) categories for each. Agreement between scores was
assessed using weighted kappas and Bland–Altman plots.
Results
The 730 included participants were predominantly male (636; 87.1%) and of white ethnicity (645;
88.5%), with a median age of 53 [interquartile range (IQR) 49–59] years. The median calculated
10-year CVD risk was 11.9% (IQR 6.8–18.4%), 8.9% (IQR 4.6–15.0%), 8.5% (IQR 4.8–14.6%) and
6.9% (IQR 4.1–11.1%) when using the Framingham, QRISK2, and full and reduced D:A:D scores,
respectively. Agreement between the different scores was generally moderate, with the highest
level of agreement being between the Framingham and QRISK2 scores (weighted kappa = 0.65) but
with most other kappa coefficients in the 0.50–0.60 range.
Conclusions
Estimates of predicted 10-year CVD risk obtained with commonly used CVD risk prediction tools
demonstrate, in general, only moderate agreement among PLWH in the UK. While further
validation with clinical endpoints is required, our findings suggest that care should be taken when
interpreting any score alone.
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SHORT COMMUNICATION
Introduction
As the population of people living with HIV (PLWH) has
aged, awareness of the impact of noninfectious causes of
morbidity in this group has increased. In particular, car-
diovascular disease (CVD) has been reported to occur
more frequently, with European guidelines now recom-
mending routine screening for CVD in PLWH [1,2].
The Framingham CVD calculator [3] was the first CVD
risk algorithm to be adopted for widespread use in the
general population, incorporating information on age,
gender, smoking, total and high-density lipoprotein (HDL)
cholesterol, systolic blood pressure, treatment for hyper-
tension and type 2 diabetes. In the UK, the National Insti-
tute for Health and Care Excellence (NICE) recommends
use of the QRISK2 calculator [4] as it is applicable to a
wider age range than the Framingham calculator
(30–84 years) and as the Framingham calculator may
overestimate CVD risk in UK populations [5,6]. QRISK2
additionally incorporates information on ethnicity, body
mass index (BMI), a history of angina or myocardial
infarction (MI) in a first-degree relative, an individual’s
own history of rheumatoid arthritis, chronic kidney dis-
ease or atrial fibrillation, and the Townsend deprivation
index (based on a person’s postcode).
While the British HIV Association (BHIVA) recom-
mends use of the QRISK2 calculator for PLWH aged
> 40 years, both QRISK2 and Framingham reportedly
underestimate risk in PLWH [6,7]. The risk equation esti-
mated in the Data Collection on Adverse Events of Anti-
HIV Drugs (D:A:D) study is the only current CVD risk
calculator derived specifically for PLWH, additionally
taking into consideration an individual’s CD4 count and
history of antiretroviral treatment (ART) use, particularly
cumulative exposure to protease inhibitors (PIs) and
nucleoside reverse transcriptase inhibitors (NRTIs) and
current use of abacavir [7]. A reduced version of the D:A:D
CVD calculator is also available which does not incorporate
ART use. While the agreement between different CVD risk
scores and clinical outcomes has been assessed in several
studies, information within a UK population of PLWH is
limited. In particular, QRISK2 has been shown to generate
a higher risk score than Framingham in some small UK
studies [8,9], although these findings have not been
consistently reported [10]. In HIV-negative individuals,
agreement between the QRISK2 and Framingham risk
calculators was good in individuals at low risk but
weakened as risk increased [11].
We describe the level of agreement between the
QRISK2, Framingham CVD and D:A:D CVD risk calcula-
tors in a large UK study of PLWH.
Methods
Two groups of PLWH (older PLWH aged ≥ 50 years and
younger PLWH aged 18–50 years) were prospectively
enrolled in the Pharmacokinetic and Clinical Observations
in People over Fifty (POPPY) study, a multicentre obser-
vational study to examine the effects of ageing and clini-
cal outcomes of PLWH in the UK and Ireland [12].
Inclusion criteria are: documented HIV infection, self-
defined white or black African ethnicity, likely route of
infection via sexual exposure, and the ability to compre-
hend the information leaflet. The younger group of PLWH
was frequency matched on gender, ethnicity, sexual ori-
entation and geographical location to the older PLWH.
The study also recruited a group of HIV-negative individ-
uals aged ≥ 50 years, who were excluded from present
analyses. Individuals were recruited to the study from
April 2013 to January 2016 and are seen approximately
annually for follow-up visits; only the baseline data were
used in the present analyses. The study was approved by
the UK National Research Ethics Service (NRES; Fulham,
London, UK; reference number 12/LO/1409) and partici-
pants provided written informed consent.
Eligible individuals were required to have complete
information for the calculation of each risk calculator.
Analyses were restricted to individuals aged > 40 years to
ensure that the Framingham risk calculator was valid,
and individuals who had previously experienced an MI or
stroke were excluded. As the POPPY study does not cap-
ture information on postcode, QRISK2 scores were calcu-
lated assuming that postcode was unavailable. However,
as a sensitivity analysis, the score was also calculated
using the postcode of the participant’s hospital as a sur-
rogate (participants from Mater Misericordiae University
Hospital Dublin, Ireland, a non-UK site with no postcode,
were excluded from this sensitivity analysis). The pub-
lished D:A:D score [7] generates an estimate of an indi-
vidual’s five-year risk of CVD; for consistency, 10-year
scores were generated using the model previously
described [7] but with the absolute 10-year survival risk
(0.9697) replacing the published absolute five-year sur-
vival risk (0.9853) (M. Law, personal communication).
Participants were stratified into ‘low’ (< 10%), ‘interme-
diate’ (10–20%) and ‘high’ (> 20%) risk categories for
each score. The weighted kappa coefficient was calculated
to determine agreement between pairs of risk scores, with
moderate agreement defined as a kappa of 0.41–0.60, and
substantial agreement as a kappa of 0.61–0.80 [13].
Absolute values of each score were assessed for signifi-
cance using unpaired t-tests and Bland–Altman plots
[14].
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Results
Of the 1073 PLWH participating in the POPPY study, 912
were aged > 40 years at recruitment and had not had a
prior MI or stroke. Of these, the 730 (80.0%) with com-
plete data for calculation of all scores were included; the
majority of those excluded from analyses were missing
information on total and/or HDL cholesterol.
Included participants were predominantly male (636;
87.1%) and of white ethnicity (645; 88.5%), with a med-
ian age of 53 [interquartile range (IQR) 49–59] years.
Current smoking was reported by 178 (24.4%) and 258
(35.3%) were ex-smokers. The median systolic blood
pressure was 129 (IQR 118–140) mmHg; 102 (14.0%)
reported receiving anti-hypertensive medication. The
median total and HDL cholesterol concentrations were
4.9 (IQR 4.2–5.5) and 1.2 (IQR 1.0–1.5) mmol/L, respec-
tively, and the median BMI was 25.6 (IQR 23.4–28.3)
kg/m2. Forty-four (6.0%), two (0.3%), eight (1.1%) and
one (0.1%) of the participants had diabetes, an estimated
glomerular filtration rate (eGFR) of ≤ 30 mL/min/
1.73 m2, atrial fibrillation and rheumatoid arthritis,
respectively. Of the HIV parameters, the median CD4
count was 630 (IQR 470–807) cells/lL, 693 (94.9%) had
ever received NRTIs for a median of 9.4 (IQR 4.8–14.3)
years, 431 (59.0%) had ever received PIs for a median
of 6.4 (IQR 2.8–11.1) years, and 97 (13.3%) were cur-
rently receiving abacavir.
The median calculated 10-year CVD risk was 11.9%
(IQR 6.8–18.4%) using the Framingham risk score, 8.9%
(IQR 4.6–15.0%) using QRISK2, 8.5% (IQR 4.8–14.6%)
using the full D:A:D score and 6.9% (IQR 4.1–11.1%)
using the reduced D:A:D score (Table 1). The estimated
10-year CVD risk was a mean of 3.0%, 2.7% and 5.7%
higher when calculated using the Framingham score than
when calculated using the QRISK2 and full and reduced
D:A:D scores, respectively. In turn, the estimated 10-year
CVD risk was 2.7% higher, on average, when calculated
using QRISK2 than when calculated using the reduced
D:A:D score, although no significant difference was seen
compared with the full D:A:D score. Finally, the esti-
mated 10-year risk was 3.0% higher, on average, when
generated using the full D:A:D score than when generated
using the reduced D:A:D score.
Overall, the numbers of individuals categorized as
being at intermediate or high CVD risk, respectively, were
276 (37.8%) and 157 (21.5%) using the Framingham
score, 228 (31.2%) and 99 (13.6%) using QRISK2, 196
(26.9%) and 108 (14.8%) using the full D:A:D score, and
183 (25.1%) and 37 (5.1%) using the reduced D:A:D
score. Agreement between scores was generally moderate,
with the highest level of agreement being between the
Framingham and QRISK2 scores (weighted kappa = 0.65)
but with most other kappa coefficients in the 0.50–0.60
range. All figures suggested greater discrepancies between
scores as risk increased (Fig. 1). Stratification by age
group (Table S1) did not reveal any trend towards
improved agreement in older individuals.
After excluding Irish participants without a UK post-
code, the median calculated QRISK2 10-year CVD risk in
the remaining 693 participants was 10.6% (IQR 5.8–
17.3%), with 328 (47.3%), 242 (34.9%) and 123 (17.8%)
classified as being at low, intermediate and high CVD
risk, respectively. Weighted kappa was 0.70 [95% confi-
dence interval (CI) 0.66–0.74] with Framingham, 0.60
(95% CI 0.55–0.64) with the full D:A:D score, and 0.51
Table 1 Estimates obtained using different cardiovascular risk equations, and agreement between equations
Cardiovascular risk score
Framingham QRISK2 D:A:D full D:A:D reduced
10-year % risk score [median (IQR)] 11.9 (6.8–18.4) 8.9 (4.6–15.0) 8.5 (4.8–14.6) 6.9 (4.1–11.1)
Cardiovascular risk classification [n (%)]
Low (< 10%) 297 (40.7) 403 (55.2) 426 (58.4) 510 (69.9)
Intermediate (10–20%) 276 (37.8) 228 (31.2) 196 (26.9) 183 (25.1)
High (> 20%) 157 (21.5) 99 (13.6) 108 (14.8) 37 (5.1)
Agreement between scores (difference calculated as column score minus row score)
Framingham
Difference in predicted 10-year risk (%) [mean (SD)] - 3.00 (4.50); P = 0.0004 2.66 (6.33); P = 0.0001 5.66 (4.94); P = 0.0001
Weighted kappa (95% CI) 0.65 (0.61–0.69) 0.53 (0.49–0.58) 0.41 (0.37–0.45)
QRISK2
Difference in predicted 10-year risk (%) [mean (SD)] - - 0.34 (6.34); P = 0.15 2.66 (4.38); P = 0.0001
Weighted kappa (95% CI) 0.60 (0.55–0.64) 0.60 (0.56–0.65)
D:A:D full
Difference in predicted 10-year risk (%) [mean (SD)] - - - 3.00 (5.59); P = 0.0001
Weighted kappa (95% CI) 0.58 (0.53–0.63)
CI, confidence interval; D:A:D, Data Collection on Adverse Events of Anti-HIV Drugs; IQR, interquartile range; SD, standard deviation.
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(95% CI 0.47–0.56) with the reduced D:A:D score, indi-
cating moderate to substantial agreement.
Discussion
Our findings show that estimates of predicted 10-year
CVD risk obtained with CVD risk prediction tools com-
monly used in the UK are, in general, only in moderate
agreement among a large UK population of PLWH. In con-
trast to previous small UK studies, estimates of CVD risk
based on the Framingham equation were significantly
higher than those based on the QRISK2 equation, which is
recommended for use in the UK in this population.
While the QRISK2 algorithm is based on UK health care
data and is often preferred for this reason, the D:A:D
equations additionally take into consideration other pre-
dictors of CVD among PLWH, including exposure to speci-
fic antiretroviral drugs and immunosuppression, factors
previously demonstrated to be associated with CVD risk
[15–17]. Our findings suggest that the full D:A:D risk
equation provides similar scores at a population level to
those of QRISK2, although with only moderate agreement
between these scores. While an optimal analysis would
include an assessment of the association between the pre-
dicted scores and absolute CVD risk based on clinical end-
points, the average age of POPPY participants and the low
expected incidence of CVD in this group mean that such
an analysis is unlikely to be feasible, at least in the short
term. Thus, while we are unable to comment on the relia-
bility of these scores for identifying those at genuinely
high CVD risk, the inclusion of HIV-specific factors in the
D:A:D model provides support for its use in this
population.
In 2017, an updated version of the QRISK calculator,
QRISK3, was released [18]. Contrary to expectations, the
presence of HIV/AIDS did not reach statistical signifi-
cance in the model because of the low number of PLWH
registered in the database, and HIV/AIDS was therefore
not included in the final model. Although the contribu-
tion of HIV itself to CVD risk remains unclear [19], it is
likely that incomplete ascertainment of HIV status among
individuals attending the primary care practices included
in the data set may have reduced the study power to
determine an association with HIV infection.
We note that the three risk equations evaluate slightly
different composite endpoints. For example, while QRISK2
evaluates an endpoint that includes angina, MI, stroke and
transient ischaemic attack, the Framingham CVD risk score
additionally incorporates coronary death, coronary insuffi-
ciency, peripheral arterial disease and heart failure into the
endpoint, whereas the D:A:D scores consider an endpoint
comprising MI, stroke, invasive cardiovascular procedures
and sudden coronary deaths only. Thus, we would expect
some difference in predicted risk between the three equa-
tions, with predicted risks for QRISK2 being somewhat
lower than those based on Framingham and potentially
higher than those based on the D:A:D scores. Thus, our
reported differences are consistent with, although some-
what greater than, these expectations.
A proportion of POPPY participants were excluded
from our analyses as information was not available on
some key factors. This was, however, largely a result of
Fig. 1 Bland–Altman plots showing levels of agreement between the four cardiovascular disease risk scores. D:A:D, Data Collection on Adverse
Events of Anti-HIV Drugs.
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cholesterol levels being unavailable from one participat-
ing clinic, and thus is unlikely to have introduced sub-
stantial bias. Although our primary analyses used the
version of QRISK2 that did not require individual post-
codes, similar findings were obtained when we utilized
the hospital postcode as a surrogate measure. POPPY par-
ticipants are of white or black African ethnicity, and the
majority of participants are men, reflecting the epidemi-
ology of HIV in this age group in the UK. While we per-
formed some stratified analyses by age group, our sample
is too small to reliably stratify by either gender or ethnic-
ity, and we cannot, therefore, comment on predicted CVD
risk in specific gender/ethnicity subgroups. Furthermore,
the published D:A:D risk score was extrapolated to give a
10-year rather than five-year risk prediction, which may
introduce errors, particularly as cumulative exposures to
some ART drugs in the POPPY study may exceed those in
the D:A:D data set used to generate the scores.
In summary, around 15% of PLWH aged > 40 years in
our UK study had a high predicted 10-year risk of CVD
based on either the QRISK2 or full D:A:D scores, support-
ing the monitoring of CVD risk and provision of CVD risk
reduction strategies as part of routine care. While a simi-
lar proportion of individuals were predicted to have a
high CVD risk, agreement between the two equations was
only moderate and thus care should be taken when inter-
preting either score alone.
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